Stocks Health care SGRY
NASDAQ · Health careSurgery Partners, Inc. (SGRY)
Surgery Partners, Inc. brought in $3.4B of revenue over the twelve months to September 30, 2026, up 2.2% from a year earlier. It posted a net loss of $87M. Operating cash flow minus capital spending left $195.6M of free cash flow in fiscal 2025. At September 30, 2026 it held $354.5M in cash against $3.1B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Surgery Partners, Inc.
- Net worth
- Surgery Partners, Inc. has a market value (market cap) of $3.5B at the latest share price, and shareholders' equity of $1.7B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $3.3B (+6.2% year on year), with a net loss of $77.9M. Over the 12 months to September 30, 2026: revenue $3.4B, net loss $87M.
- Cash flow
- In fiscal 2025 operations brought in $274.3M of cash; after $78.7M of capital spending, free cash flow was $195.6M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Surgery Partners, Inc.'s next report is expected around March 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Surgery Partners, Inc. does
Surgery Partners, Inc. is registered with the SEC under industry code SIC 8062 (Services-General Medical & Surgical Hospitals, NEC). Its shares trade on NASDAQ under the ticker SGRY.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3.3B | -$77.9M | -$0.61 | $195.6M |
| 2024 | $3.1B | -$168.1M | -$1.33 | $209.7M |
| 2023 | $2.7B | -$11.9M | -$0.09 | $205M |
| 2022 | $2.5B | -$54.6M | -$0.59 | $78.2M |
| 2021 | $2.2B | -$70.9M | -$1.12 | $29.5M |
| 2020 | $1.9B | -$116.1M | -$3.19 | $204M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where SGRY ranks in Health care
Latest SEC filings
What Surgery Partners, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 0.8% to $815.3M versus the same quarter last year; diluted EPS -$0.16 versus -$0.18.
- November 9, 2026Additional proxy material DEFA14A
- November 9, 2026Additional proxy material DEFA14A
- November 9, 2026
- November 9, 2026Additional proxy material DEFA14A
- November 9, 2026
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- October 28, 2026Additional proxy material DEFA14A
- October 27, 2026Additional proxy material DEFA14A
- October 26, 2026Additional proxy material DEFA14A
What is SGRY worth? A DCF from its reported cash flow
Insider trades
What the people running Surgery Partners, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $304.7K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 18, 2026 | DeLuca TeresaDirector | Bought | 11,250 | $161.2K |
| August 18, 2026 | DeLuca TeresaDirector | Bought | 10,000 | $143.5K |
| June 18, 2026 | Hendrix Blair EDirector | Received as pay | 34,364 | $500K |
| June 5, 2026 | Turner BrentDirector | Received as pay | 11,670 | $160K |
| June 5, 2026 | DeLuca TeresaDirector | Received as pay | 11,670 | $160K |
| June 5, 2026 | Dean Lloyd HDirector | Received as pay | 11,670 | $160K |
| June 5, 2026 | Adlerz Clifford GDirector | Received as pay | 11,670 | $160K |
| June 5, 2026 | Forese Laura LDirector | Received as pay | 11,670 | $160K |
Who owns SGRY
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| BCPE Seminole Holdings II Intermediate, LP13D, may seek influence with 3 related filers | 22.96% | October 26, 2026 |
| Janus Henderson Group PLC13G, passive with 1 related filers | 10.2% | November 14, 2025 |
| Pentwater Capital Management LP13G, passive with 1 related filers | 9.7% | May 15, 2026 |
| Glenview Capital Management, LLC13G, passive with 1 related filers | 5.4% | October 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 187 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Bain Capital Investors LLC | 49,946,972 | 0 |
| Jupiter Topco LLC | 13,882,155 | new |
| Pentwater Capital Management LP | 11,630,000 | -1,025,000 |
| UBS Group AG | 8,573,413 | -1,618,368 |
| BlackRock, Inc. | 6,241,503 | +580,715 |
| King Street Capital Management, L.P. | 6,058,141 | -4,171,589 |
| Dimensional Fund Advisors LP | 4,943,713 | -352,698 |
| Clearbridge Investments, LLC | 3,823,179 | -294,877 |
| Vanguard Portfolio Management LLC | 3,737,712 | +109,281 |
| Vanguard Capital Management LLC | 3,509,535 | +78,740 |
| Davidson Kempner Capital Management LP | 3,336,464 | 0 |
| Hsbc Holdings PLC | 2,958,912 | +1,043,244 |
| Fmr LLC | 2,149,009 | -42,456 |
| State Street Corp | 2,140,905 | +187,127 |
| Geode Capital Management, LLC | 2,116,579 | +114,205 |
| Nomura Holdings Inc | 1,525,108 | +801,868 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1,471,492 | -117,876 |
| LMR Partners LLP | 1,360,587 | +260,587 |
| Morgan Stanley | 1,232,751 | +220,574 |
| Bank of America Corp | 1,212,766 | -27,216 |
Insiders
14 insiders reported holding 2,186,916 shares in total, about $58.5M at the last price.
| Holder | Shares |
|---|---|
| Evans Jason EricChief Executive Officer | 920,386 |
| Baldock JenniferChief Admin & Dev Officer | 326,474 |
| Doherty David TChief Financial Officer | 221,679 |
| Oppenheimer Justin RobertCOO & National Group President | 120,259 |
| Brittenham MarissaChief Strategy Officer | 94,196 |
| Turner BrentDirector | 86,594 |
| Burkhalter DanielleChief Human Resources Officer | 76,864 |
| Webb William TrentonAmerican Group President | 74,249 |
| Adlerz Clifford GDirector | 69,104 |
| DeLuca TeresaDirector | 68,093 |
Questions about SGRY
What does Surgery Partners, Inc. do?
Surgery Partners, Inc. is a company in the Health care sector, listed on NASDAQ as SGRY. Its shares trade on NASDAQ under the ticker SGRY.
What is Surgery Partners, Inc.'s net worth?
Surgery Partners, Inc. has a market value (market cap) of $3.5B at the latest share price, and shareholders' equity of $1.7B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Surgery Partners, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $87M on revenue of $3.4B.
How much revenue does Surgery Partners, Inc. make?
Over the twelve months to September 30, 2026 Surgery Partners, Inc. reported revenue of $3.4B. That is 2.2% more than a year earlier.
When did Surgery Partners, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Surgery Partners, Inc.'s next earnings report?
Surgery Partners, Inc.'s next report is expected around March 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SGRY with
Follow SGRY
Get an email when Surgery Partners, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Surgery Partners, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.